An open-label, randomized, single dose, two period, crossover study to determine the bioequivalence between valsartan 160 mg pediatric final market image (FMI) formulation (solution) and clinical service form (CSF) of valsartan 160 mg extemporaneous suspension in healthy adult volunteers.
Latest Information Update: 22 Aug 2017
At a glance
- Drugs Valsartan (Primary)
- Indications Essential hypertension; Heart failure; Hypertension; Postmyocardial infarction
- Focus Pharmacokinetics
- Sponsors Novartis
- 22 Aug 2017 New trial record